Stemtech Corporation (STEK) develops and distributes stem cell nutrition and stemceutical wellness products, including plant-based nutritional supplements, skin care and oral care products. Its updates commonly cover product availability, inventory funding, the Stemtech BioSciences e-commerce retail channel, and the company's network marketing model built around Independent Business Partners.
Company news also addresses scientific and advisory appointments, regulatory alignment for global wellness products, and international distribution initiatives through subsidiaries and joint ventures in markets such as India and the Gulf Cooperation Council region. Stemtech operates as a Nevada public company that became publicly traded in 2021 after continuing operations under new leadership in 2018.
Stemtech Corporation (OTCQB:STEK) announced a joint venture with Innoventure Dynamic LLP to form Stemtech HealthSciences India Private Limited (SHIPL) dated October 23, 2025. Stemtech will hold 51% and Innoventure 49% of the JV; India startup funding will be provided entirely by Innoventure.
John W. Meyer will serve as Managing Director for SHIPL. The JV will distribute all Stemtech product lines—stemceuticals, skin care, oral care and pet products—with an eventual plan to manufacture in India and target a population of over 1.4 billion.
Stemtech (OTCQB:STEK) announced on October 20, 2025 that core products are now available for shipment after supply delivery and manufacturing challenges delayed order fulfillment. The company cited tariffs and capital constraints on internationally sourced raw materials as causes of prior backorders.
U.S. backorders are being cleared, inventory for Mexico is being produced and will ship shortly, and shipments to Canada and Ecuador are en route. Management highlighted market demand with a $4.6 billion stem cell market in 2024 and a projected $30 billion market by 2030.
Stemtech Corporation (OTC: STEK) announced an exclusive distribution licensing agreement with Energy International Development Co., Ltd. to sell Stemtech products in Taiwan, R.O.C. on October 9, 2025. The company said products are already manufactured in Taiwan and will be distributed through the licensee's retail networks. Management described the licensing model as a way to generate revenue via licensing fees and manufacturing without the costs of direct operations, while the licensee projects strong growth in the territory.
The announcement emphasizes market expansion, local manufacturing and a low‑overhead licensing strategy to monetize Stemtech's stem cell nutrition products in Taiwan.
Stemtech Corporation (OTCQB:STEK) has announced a significant collaboration with renowned clinical physician Dr. Sabine Hazan, MD to conduct clinical trials on their RCM System of stem cell nutrition products. Dr. Hazan, known for her expertise in gastroenterology and natural remedies, will evaluate the effects of Stemtech's products on the microbiome.
The research will focus on Stemtech's three key products: stemrelease3™, StemFlo Advanced®, and MigraStem®. The company has reported cumulative sales of over $600 million USD with less than 2% returns. Stemtech currently operates in the United States, Mexico, Ecuador, Canada, and Taiwan.
This partnership aims to document the benefits of Stemtech's natural, plant-based approach to stem cell nutrition and inflammation management through transparent, data-driven clinical trials.
Stemtech Corporation (OTCQB:STEK) has announced the launch of StemPets™, a revolutionary pet nutraceutical supplement, available in the U.S. starting June 2025 and in Mexico two weeks later. The product, designed for dogs and cats, is a 100% plant-based anti-aging and longevity formula featuring anacardic acid as its key ingredient.
The company holds exclusive distribution rights for this AAFCO-registered compound. StemPets™ aims to provide benefits including increased energy levels, shinier coat, healthier skin, better digestion, and improved joint health. This launch represents Stemtech's strategic entry into the pet wellness market, which is projected to exceed $500 billion globally by 2030.
Stemtech (STEK) has announced strategic leadership changes and plans to launch StemPets™, their new pet health product line, in early Q2 2025. The company aims to capture a share of the global pet care market, projected to reach $303 billion by 2027.
Key leadership appointments include:
- Alejandro Carrillo promoted to VP of Global Operations after 10 years with the company
- Srilakshmi Vadlapatla appointed as Global Accounts Manager, set to become CFO
- Manuel Ramirez Garcia joins as Director of Global Sales & Field Development
The company announced the departure of James S. Cardwell from his CFO position. These appointments align with Stemtech's strategy to expand its stem cell nutrition business globally and enter the pet healthcare market.
Stemtech (OTCQB:STEK) is positioning itself as a leader in the wellness and anti-aging sectors with its natural, plant-based nutritional stemceuticals™. The company operates in a rapidly expanding market, with the Global Wellness Economy reaching $6.3 trillion and projected to hit $9 trillion by 2028, currently four times larger than the global pharmaceutical industry.
The company's product portfolio includes stemrelease3™, StemFlo™ Advanced, MigraStem®, OraStem® Toothpaste, and recent launches like Cellect One® Shield and Cellect One® Rapid Renew Stem Cell Peptide Night Cream. Stemtech plans to enter the pet wellness market with StemPets™ in April 2025, targeting the $303 billion global pet wellness market.
Stemtech (OTCQB:STEK) announced a proposed Reverse Takeover (RTO) of Eevia Health Plc, following its planned merger with Seacret Direct (VIÁGO). Under the RTO, Eevia will acquire Stemtech's assets and liabilities, with Stemtech owning approximately 85% of Eevia post-transaction.
The strategic combination aims to create a vertically integrated health and wellness entity, utilizing Eevia's Finnish production facility for manufacturing Stemtech and VIÁGO's products. The merged entity will combine Stemtech's stem cell nutrition technology with VIÁGO's lifestyle offerings, serving over 250,000 affiliated members across 40+ countries.
The transaction includes Stemtech issuing 13 million preferred shares at $2.50, convertible to 50% of common stock. The deal completion is subject to due diligence, definitive agreements, and regulatory approvals.
Stemtech (OTCQB:STEK) has signed a merger agreement with Seacret Direct / VIÁGO through the issuance of 13 million preferred shares valued at $2.50 per share. The merger is expected to double Stemtech's revenue and create a vertically integrated company focused on health, longevity, and lifestyle solutions.
The transaction completion remains subject to conditions, including Seacret Direct / VIÁGO's audit, consents, and authorizations. The merged entity anticipates doubled revenue forecast for 2025 with planned cost synergies, aiming to deliver positive bottom-line results through optimization and existing growth trajectories.